Stay updated on Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:59:36.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage. This change likely represents an update or modification related to the effectiveness or safety evaluation of Pembrolizumab (MK-3475) in combination with or without Bevacizumab for the treatment of recurrent glioblastoma multiforme (GBM).
    Difference
    0.1%
    Check dated 2024-06-06T14:28:54.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the health conditions and prior treatments required for inclusion in the study. This change provides more specific information about the histological confirmation and treatment history needed for participants with Grade IV malignant glioma.
    Difference
    38%
    Check dated 2024-05-22T20:55:12.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:33:12.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Bevacizumab in Recurrent GBM Clinical Trial page.